Quidel secures osteoporosis collaborations

These partnerships will leverage Quidel’s global capabilities to collaborate with osteoporosis research institutions for the development of new markers which may benefit osteoporosis and post-menopausal patients.

“With these strategic business partnerships, Quidel is poised to advance the development of markers in the field of bone health and osteoporosis,” said Noah Nasser, general manager of the Specialty Products Group. “These alliances provide a gateway for Quidel to fuel and further expand its growth and development in the global bone health industry, by tapping into new, international markets and sales opportunities,” he added.

Quidel’s two-year partnership with Nordic Bioscience Diagnostics is a co-marketing and sales alliance for promoting both company’s diagnostic bone assays into the Nordic and Baltic states, creating a unique diagnostic solution for analyzing bone turnover.

In return, Quidel will sell Nordic Bioscience Diagnostics’ Serum CrossLaps ELISA (CTX-I, an in vitro diagnostic kit for measuring bone resorption) in the US market. The tests will be positioned as a package for measuring total bone turnover. This partnership with Nordic Bioscience Diagnostics enables Quidel to provide clinicians and researchers with an unprecedented opportunity to measure bone turnover and better understand the underlying nature of osteoporosis and related diseases.

The co-marketing agreement with Cambrex Bio Science Walkersville, enables Quidel’s Metra Helical Peptide assay to be combined with Cambrex’s OsteoAssay Human Bone Plate, creating an integrated solution for measuring bone resorption.